What is the projected market valuation of the Agnosia Treatment Market by 2035?

The projected market valuation for the Agnosia Treatment Market by 2035 is 0.1871 USD Million. Read More

What was the overall market valuation of the Agnosia Treatment Market in 2024?

The overall market valuation of the Agnosia Treatment Market in 2024 was 0.12 USD Million. Read More

What is the expected CAGR for the Agnosia Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Agnosia Treatment Market during the forecast period 2025 - 2035 is 4.12%. Read More

Which companies are key players in the Agnosia Treatment Market?

Key players in the Agnosia Treatment Market include Roche, Novartis, Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck & Co., and Sanofi. Read More

What are the main types of agnosia addressed in the treatment market?

The main types of agnosia addressed in the treatment market include auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Read More

What was the valuation for the diagnosis segment in the Agnosia Treatment Market?

The valuation for the diagnosis segment in the Agnosia Treatment Market was 0.04 USD Million for Computed Tomography (CT) and 0.05 USD Million for Magnetic Resonance Imaging (MRI). Read More

What are the causes of agnosia as per the market segments?

The causes of agnosia as per the market segments include Alzheimer's disease, Pick's disease, MELAS, and Balint's syndrome, with respective valuations of 0.05, 0.02, 0.02, and 0.03 USD Million. Read More

What treatment options are available in the Agnosia Treatment Market?

Treatment options in the Agnosia Treatment Market include surgery, antibiotics for cerebral abscess, and radiation of brain tumor, with valuations ranging from 0.03 to 0.08 USD Million. Read More

How does the market for visual agnosia compare to other types?

The market for visual agnosia is valued at 0.04 USD Million to 0.06 USD Million, making it one of the more prominent types compared to others. Read More

What is the significance of the projected growth in the Agnosia Treatment Market?

The projected growth in the Agnosia Treatment Market indicates a rising awareness and potential advancements in treatment options, driven by a CAGR of 4.12% from 2025 to 2035. Read More

Agnosia Treatment Market

ID: MRFR/Pharma/3610-HCR

80 Pages

Vikita Thakur

Last Updated: May 15, 2026

Agnosia Treatment Market: By Diagnosis (CT, MRI) Causes (Alzheimer's Disease, Pick's Disease, Melas, Balint's Syndrome) Type (Auditory Agnosia, Gustatory Agnosia, Olfactory Agnosia, Tactile Agnosia, Visual Agnosia) Treatment - Forecast till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Diagnosis (USD Million)
  1. 4.1.1 Computed Tomography (CT)
  2. 4.1.2 Magnetic Resonance Imaging (MRI)
  3. 4.1.3 Others
2. 4.2 Healthcare, BY Causes (USD Million)
  1. 4.2.1 Alzheimer's disease
  2. 4.2.2 Pick's disease
  3. 4.2.3 MELAS
  4. 4.2.4 Balint's syndrome
3. 4.3 Healthcare, BY Type (USD Million)
  1. 4.3.1 auditory agnosia
  2. 4.3.2 gustatory agnosia
  3. 4.3.3 olfactory agnosia
  4. 4.3.4 tactile agnosia
  5. 4.3.5 visual agnosia
  6. 4.3.6 Others
4. 4.4 Healthcare, BY Treatment (USD Million)
  1. 4.4.1 surgery
  2. 4.4.2 antibiotics for cerebral abscess
  3. 4.4.3 radiation of brain tumor
5. 4.5 Healthcare, BY Region (USD Million)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY CAUSES
5. 6.5 US MARKET ANALYSIS BY TYPE
6. 6.6 US MARKET ANALYSIS BY TREATMENT
7. 6.7 CANADA MARKET ANALYSIS BY DIAGNOSIS
8. 6.8 CANADA MARKET ANALYSIS BY CAUSES
9. 6.9 CANADA MARKET ANALYSIS BY TYPE
10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY DIAGNOSIS
13. 6.13 GERMANY MARKET ANALYSIS BY CAUSES
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT
16. 6.16 UK MARKET ANALYSIS BY DIAGNOSIS
17. 6.17 UK MARKET ANALYSIS BY CAUSES
18. 6.18 UK MARKET ANALYSIS BY TYPE
19. 6.19 UK MARKET ANALYSIS BY TREATMENT
20. 6.20 FRANCE MARKET ANALYSIS BY DIAGNOSIS
21. 6.21 FRANCE MARKET ANALYSIS BY CAUSES
22. 6.22 FRANCE MARKET ANALYSIS BY TYPE
23. 6.23 FRANCE MARKET ANALYSIS BY TREATMENT
24. 6.24 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
25. 6.25 RUSSIA MARKET ANALYSIS BY CAUSES
26. 6.26 RUSSIA MARKET ANALYSIS BY TYPE
27. 6.27 RUSSIA MARKET ANALYSIS BY TREATMENT
28. 6.28 ITALY MARKET ANALYSIS BY DIAGNOSIS
29. 6.29 ITALY MARKET ANALYSIS BY CAUSES
30. 6.30 ITALY MARKET ANALYSIS BY TYPE
31. 6.31 ITALY MARKET ANALYSIS BY TREATMENT
32. 6.32 SPAIN MARKET ANALYSIS BY DIAGNOSIS
33. 6.33 SPAIN MARKET ANALYSIS BY CAUSES
34. 6.34 SPAIN MARKET ANALYSIS BY TYPE
35. 6.35 SPAIN MARKET ANALYSIS BY TREATMENT
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY CAUSES
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TYPE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY DIAGNOSIS
42. 6.42 CHINA MARKET ANALYSIS BY CAUSES
43. 6.43 CHINA MARKET ANALYSIS BY TYPE
44. 6.44 CHINA MARKET ANALYSIS BY TREATMENT
45. 6.45 INDIA MARKET ANALYSIS BY DIAGNOSIS
46. 6.46 INDIA MARKET ANALYSIS BY CAUSES
47. 6.47 INDIA MARKET ANALYSIS BY TYPE
48. 6.48 INDIA MARKET ANALYSIS BY TREATMENT
49. 6.49 JAPAN MARKET ANALYSIS BY DIAGNOSIS
50. 6.50 JAPAN MARKET ANALYSIS BY CAUSES
51. 6.51 JAPAN MARKET ANALYSIS BY TYPE
52. 6.52 JAPAN MARKET ANALYSIS BY TREATMENT
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY CAUSES
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TYPE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
57. 6.57 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
58. 6.58 MALAYSIA MARKET ANALYSIS BY CAUSES
59. 6.59 MALAYSIA MARKET ANALYSIS BY TYPE
60. 6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT
61. 6.61 THAILAND MARKET ANALYSIS BY DIAGNOSIS
62. 6.62 THAILAND MARKET ANALYSIS BY CAUSES
63. 6.63 THAILAND MARKET ANALYSIS BY TYPE
64. 6.64 THAILAND MARKET ANALYSIS BY TREATMENT
65. 6.65 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
66. 6.66 INDONESIA MARKET ANALYSIS BY CAUSES
67. 6.67 INDONESIA MARKET ANALYSIS BY TYPE
68. 6.68 INDONESIA MARKET ANALYSIS BY TREATMENT
69. 6.69 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
70. 6.70 REST OF APAC MARKET ANALYSIS BY CAUSES
71. 6.71 REST OF APAC MARKET ANALYSIS BY TYPE
72. 6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
75. 6.75 BRAZIL MARKET ANALYSIS BY CAUSES
76. 6.76 BRAZIL MARKET ANALYSIS BY TYPE
77. 6.77 BRAZIL MARKET ANALYSIS BY TREATMENT
78. 6.78 MEXICO MARKET ANALYSIS BY DIAGNOSIS
79. 6.79 MEXICO MARKET ANALYSIS BY CAUSES
80. 6.80 MEXICO MARKET ANALYSIS BY TYPE
81. 6.81 MEXICO MARKET ANALYSIS BY TREATMENT
82. 6.82 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
83. 6.83 ARGENTINA MARKET ANALYSIS BY CAUSES
84. 6.84 ARGENTINA MARKET ANALYSIS BY TYPE
85. 6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY CAUSES
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY CAUSES
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TYPE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY CAUSES
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TYPE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
99. 6.99 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
100. 6.100 REST OF MEA MARKET ANALYSIS BY CAUSES
101. 6.101 REST OF MEA MARKET ANALYSIS BY TYPE
102. 6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
111. 6.111 HEALTHCARE, BY CAUSES, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY CAUSES, 2024 TO 2035 (USD Million)
113. 6.113 HEALTHCARE, BY TYPE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
115. 6.115 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Million)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.2.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY TREATMENT, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.3.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.3.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.3.4 BY TREATMENT, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.4.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.4.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.4.4 BY TREATMENT, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.5.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.5.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.5.4 BY TREATMENT, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.6.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.6.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.6.4 BY TREATMENT, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.7.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.7.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.7.4 BY TREATMENT, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.8.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.8.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.8.4 BY TREATMENT, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.9.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.9.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.9.4 BY TREATMENT, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.10.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.10.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.10.4 BY TREATMENT, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.11.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.11.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.11.4 BY TREATMENT, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.12.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.12.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.12.4 BY TREATMENT, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.13.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.13.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.13.4 BY TREATMENT, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.14.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.14.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.14.4 BY TREATMENT, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.15.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.15.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.15.4 BY TREATMENT, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.16.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.16.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.16.4 BY TREATMENT, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.17.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.17.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.17.4 BY TREATMENT, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.18.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.18.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.18.4 BY TREATMENT, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.19.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.19.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.19.4 BY TREATMENT, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.20.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.20.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.20.4 BY TREATMENT, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.21.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.21.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.21.4 BY TREATMENT, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.22.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.22.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.22.4 BY TREATMENT, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.23.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.23.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.23.4 BY TREATMENT, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.24.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.24.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.24.4 BY TREATMENT, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.25.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.25.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.25.4 BY TREATMENT, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.26.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.26.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.26.4 BY TREATMENT, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.27.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.27.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.27.4 BY TREATMENT, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.28.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.28.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.28.4 BY TREATMENT, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.29.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.29.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.29.4 BY TREATMENT, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.30.2 BY CAUSES, 2025-2035 (USD Million)
  3. 7.30.3 BY TYPE, 2025-2035 (USD Million)
  4. 7.30.4 BY TREATMENT, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Agnosia Treatment Market Segmentation

Agnosia Treatment Market By Diagnosis (USD Million, 2025-2035)

Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Others

Agnosia Treatment Market By Causes (USD Million, 2025-2035)

Alzheimer's disease
Pick's disease
MELAS
Balint's syndrome

Agnosia Treatment Market By Type (USD Million, 2025-2035)

auditory agnosia
gustatory agnosia
olfactory agnosia
tactile agnosia
visual agnosia
Others

Agnosia Treatment Market By Treatment (USD Million, 2025-2035)

surgery
antibiotics for cerebral abscess
radiation of brain tumor

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”